| ArQule, Inc. | $60 Million | Joint Bookrunner | Follow-On Offering | April 2012 |
| OncoGenex Pharmaceuticals, Inc. | $58 Million | Joint Bookrunner | Follow-On Offering | March 2012 |
| Amicus Therapeutics, Inc. | $66 Million | Joint Bookrunner | Follow-On Offering | March 2012 |
| Array BioPharma | $60 Million | Joint Bookrunner | Follow-On Offering | February 2012 |
| Cempra, Inc. | $58 Million | Joint Bookrunner | Initial Public Offering | February 2012 |
| Verastem, Inc. | $63 Million | Joint Bookrunner | Initial Public Offering | January 2012 |
| Chelsea Therapeutics, Ltd. | $24 Million | Sole Bookrunner | Follow-On Offering | January 2012 |
| Vical Incorporated | $50 Million | Joint Bookrunner | Follow-On Offering | January 2012 |
| MELA Sciences, Inc. | $16 Million | Sole Bookrunner | Registered Direct Offering | December 2011 |
| Orexigen Therapeutics | $90 Million | Sole Manager | Unit Offering | December 2011 |
| Puma Biotechnology | $60 Million | Exclusive Advisor & Lead Placement Agent | Private Placement | November 2011 |
| Kythera Biopharmaceuticals | $37 Million | Sole Placement Agent | Private Placement | September 2011 |
| Zogenix | $61 Million | Joint Bookrunner | Follow-On Offering | September 2011 |
| InterMune | $265 Million | Co-Manager | Follow-On / Convertible Senior Notes | September 2011 |
| Endocyte | $82 Million | Joint Bookrunner | Follow-On Offering | July 2011 |
| NeurogesX | $20 Million | Sole Placement Agent | Private Placement | July 2011 |
| Ventrus Biosciences | $52 Million | Joint Bookrunner | Re-IPO | July 2011 |
| Vanguard Health Systems | $518 Million | Co-Manager | Initial Public Offering | June 2011 |
| Zogenix | $32 Million | Exclusive Advisor | Structured Royalty Financing | June 2011 |
| Nationwide Better Health | Not Disclosed | Exclusive Advisor | Productivity Solutions Assets Sale | June 2011 |
| CynoSure | $25 Million | Exclusive Advisor | Acquisition of Aesthetic Business of HOYA ConBio | June 2011 |
| ArthroCare Corporation | Not Disclosed | Exclusive Financial Advisor | Sale of Parallax Assets | June 2011 |
| Achillion Pharmaceuticals | $65 Million | Joint Bookrunner | Follow-On Offering | June 2011 |
| Anthera Pharmaceuticals | $58 Million | Joint Bookrunner | Follow-On Offering | June 2011 |
| Radius Health | $66 Million | Sole Agent | Private Placement | May 2011 |
| NPS Pharmaceuticals | $114 Million | Joint Bookrunner | Follow-On Offering | April 2011 |
| HCA | $4.4 Billion | Co-Manager | (IPO) Initial Public Offering | March 2011 |
| Gilead | $1.0 Billion | Co-Manager | Senior Unsecured Notes | March 2011 |
| Fluidigm | $86 Million | Co-Manager | (IPO) Initial Public Offering | February 2011 |
| Endocyte | $86 Million | Joint Bookrunner | (IPO) Initial Public Offering | February 2011 |
| Seattle Genetics | $178 Million | Co-Lead Manager | Follow-On Offering | February 2011 |
| Pharmasset | $176 Million | Co-Manager | Follow-On Offering | January 2011 |
| Corcept Therapeutics | $45 Million | Joint Bookrunner | Follow-On Offering | January 2011 |
| ArQule | $50 Million | Joint Bookrunner | Follow-On Offering | January 2011 |
| Amarin | $105 Million | Joint Bookrunner | Follow-On Offering | January 2011 |
